Medline Inc. (MDLN) Reports Q2 EPS of $0.50

Medline Inc. (NASDAQ: MDLN) reported Q2 EPS of $0.50, versus $0.83 reported last year. Revenue for the quarter came in at $7.7 billion, versus $6.89 billion reported last year.

2026 Guidance
The Company is updating its full year 2026 outlook for Organic Sales2 growth to 9.0% to 10.0%, compared to its previous outlook of 8.5% to 9.5%, reflecting strong existing and new customer demand. The Company updated its Adjusted EBITDA2 outlook to $3.3 billion to $3.4 billion, compared to its previous outlook of $3.5 to $3.6 billion, primarily reflecting higher than expected inflationary pressure from the Middle East conflict, increased operational investments to support customer demand, quality remediation efforts, and retail channel softness. The Organic Sales2 reflects IEEPA tariff customer repayments and the Adjusted EBITDA2 outlook does not reflect the benefit of IEEPA tariff refunds.

For earnings history and earnings-related data on Medline Inc. (MDLN) click here.

You May Also Be Interested In

• Anthropic plans IPO potentially exceeding SpaceX's $86B record - Bloomberg
• Deere & Co. (DE) Tops Q3 EPS by 41c, raises guidance
• Musalem: strong growth and investment influencing bond market - CNBC